Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 24 clinical trials
Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC

To compare the efficacy and safety of gefitinib combined with bevacizumab and gefitinib in the treatment of L858R positive mutation in exon 21 of EGFR gene in advanced NSCLC.

  • 0 views
  • 25 Jan, 2021
  • 1 location
Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC (FL-ALTER)

Gefitinib is currently the standard-of-care for patients with activating-EGFR mutant advanced non-small cell lung cancer (NSCLC). However, ~30-40% patients are still nonresponsive, and

recurrent non-small cell lung cancer
cancer chemotherapy
gefitinib
targeted therapy
EGFR
  • 1 views
  • 17 Feb, 2022
ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

To assess the efficacy and safety of ASK120067 versus a standard of care epidermal growth factor receptor tyrosine kinase inhibitor Gefitinib in patients with locally advanced or Metastatic Non

  • 0 views
  • 26 May, 2022
  • 3 locations
A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

The main purpose of this study is to evaluate the safety and efficacy of Apatinib in combination with Gefitinib as compared to placebo in combination with Gefitinib in participants with stage B

  • 12 views
  • 24 Feb, 2022
  • 1 location
A Phase III Randomized Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.

This study aims to compare the efficacy of intercalating chemotherapy (gefitinib and pemetrexed/cisplatin) and chemotherapy (navelbine/cisplatin) in completely resected NSCLC with common EGFR

  • 0 views
  • 22 Jan, 2021
A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer (FWD1509)

The purpose of this study is to characterize the safety and tolerability of FWD1509 MsOH in advanced NSCLC patients and establish the maximum tolerable dose (MTD), recommended phase 2 dose (RP2D) in advanced NSCLC patients.

erbb2
HER2
systemic therapy
EGFR
kidney function test
  • 0 views
  • 04 Oct, 2022
  • 1 location
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective Study (SELECT-2)

This is a nationwide, multicenter and prospective cohort study. The purpose of this study is to evaluate the synergistic effect and safety of Elemene plus TKIs in EGFR-mutated advanced non-small cell lung cancer.

cancer
cancer chemotherapy
gefitinib
EGFR
osimertinib
  • 0 views
  • 11 Jul, 2022
  • 7 locations
Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer

This is a multi-center phase II randomized controlled study to assess the efficacy of Gefitinib alone and Gefitinib combinating with Pemetrexed/platinum on patients with brain metastasis from

cancer
cancer chemotherapy
gefitinib
pemetrexed
EGFR
  • 16 views
  • 13 Mar, 2022
MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib (MELROSE)

randomized phase 3 study clearly demonstrated the superiority of osimertinib compared with erlotinib or gefitinib in EGFR mutated nonpretreated NSCLC (median PFS of 18.9 months versus 10.2 months).

epidermal growth factor receptor
egfr t790m
pemetrexed
stage iv non-small cell lung cancer
lung adenocarcinoma
  • 6 views
  • 08 Feb, 2022
  • 4 locations
A Phase I Dose Escalation Study for Patients With Recurrent Malignant Gliomas

This is a clinical trial (a type of research study). Clinical trials include only patients who choose to take part. You are being asked to take part in this study because you have a brain tumor that continued to grow despite prior therapy. Currently, there is no known effective treatment …

  • 7 views
  • 07 Nov, 2020
  • 1 location